Results 91 to 100 of about 37,818 (285)

Health Care Payment Incentives: A Comparative Analysis of Reforms in Taiwan, Korea and China [PDF]

Payment incentives have significant consequences for the equity and efficiency of a health care system, and have recently come to the fore in health policy reforms.
Karen Eggleston, Chee-Ruey Hsieh
core  

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

The Taiwanese health care system under efficiency scrutiny [PDF]

This thesis describes the status quo of the Taiwanese health care system in the year 2000, 5 years after the reforms, analyses the economic efficiency of single components of the new health care system and searches for possible solutions to solve ...
Schreyögg, Jonas
core  

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Key factors associated with China’s basic medical insurance fund revenue-expenditure balance: a grey relational analysis

Cost Effectiveness and Resource Allocation
Introduction The financial equilibrium of China’s Basic Medical Insurance Fund (BMIF) is pivotal, as it directly influences the sustainability, equity, and stability of the healthcare security system.
Guangwen Gong, Wang Dan, Hu Wei, Li Xiping   +3 more
doaj   +1 more source

Implementation of a billable transitional care model for stroke patients: the COMPASS study

BMC Health Services Research, 2019
Background The COMprehensive Post-Acute Stroke Services (COMPASS) pragmatic trial compared the effectiveness of comprehensive transitional care (COMPASS-TC) versus usual care among stroke and transient ischemic attack (TIA) patients discharged home from ...
Sabina B. Gesell, Cheryl D. Bushnell, Sara B. Jones, Sylvia W. Coleman, Samantha M. Levy, James G. Xenakis, Barbara J. Lutz, Janet Prvu Bettger, Janet Freburger, Jacqueline R. Halladay, Anna M. Johnson, Anna M. Kucharska-Newton, Laurie H. Mettam, Amy M. Pastva, Matthew A. Psioda, Meghan D. Radman, Wayne D. Rosamond, Mysha E. Sissine, Joanne Halls, Pamela W. Duncan   +19 more
doaj   +1 more source

Innovative Financing in Early Recovery: The Liberia Health Sector Pool Fund - Working Paper 288 [PDF]

In post-conflict Liberia, the National Health Plan set out a process for transitioning from emergency to sustainability under government leadership.
Jacob Hughes, Amanda Glassman, and Walter Gwenigale
core  

Physician Reimbursement Mechanisms as Social Constraints: An Historical Critique of Douglass North's Theory of Institutional Evolution

, 1997
Douglass North, in his seminal workInstitutions, Institutional Change, and Economic Performance, defined institutions as “the humanly devised constraints that shape human interaction,” existing within a hierarchical continuum ranging—in order of ...
Philip C. Williams
core   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source